BMB Reports : eISSN 1976-670X

Cited by CrossRef (13)

  1. Luyan Liu, Yi Wu, Kaiyan Ye, Meichun Cai, Guanglei Zhuang, Jieyi Wang. Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking. Front. Pharmacol. 2022;13
    https://doi.org/10.3389/fphar.2022.924197
  2. Shreyas Gaikwad, Manas Yogendra Agrawal, Itishree Kaushik, Sharavan Ramachandran, Sanjay K. Srivastava. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Seminars in Cancer Biology 2022;86:137
    https://doi.org/10.1016/j.semcancer.2022.03.014
  3. Shadma Fatima, Yafeng Ma, Azadeh Safrachi, Sana Haider, Kevin J. Spring, Fatemeh Vafaee, Kieran F. Scott, Tara L. Roberts, Therese M. Becker, Paul de Souza. Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers 2022;14:1669
    https://doi.org/10.3390/cancers14071669
  4. Carmine Valenza, Graziella Rizzo, Maria Ilenia Passalacqua, Laura Boldrini, Chiara Corti, Dario Trapani, Giuseppe Curigliano. Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives. Ther Adv Med Oncol 2023;15:175883592211461
    https://doi.org/10.1177/17588359221146129
  5. Sophie Rovers, Annelies Janssens, Jo Raskin, Patrick Pauwels, Jan P. van Meerbeeck, Evelien Smits, Elly Marcq. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines 2022;10:673
    https://doi.org/10.3390/biomedicines10030673
  6. Antony W. Burgess. Regulation of Signaling from the Epidermal Growth Factor Family. J. Phys. Chem. C 2022
    https://doi.org/10.1021/acs.jpcc.2c04156
  7. Alok K. Mishra, Amjad Ali, Shubham Dutta, Shahid Banday, Sunil K. Malonia. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60
    https://doi.org/10.3390/diseases10030060
  8. Antony W. Burgess. Regulation of Signaling from the Epidermal Growth Factor Family. J. Phys. Chem. B 2022;126:7475
    https://doi.org/10.1021/acs.jpcb.2c04156
  9. Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Eleni Karapedi, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Kostas A. Papavassiliou, Michalis V. Karamouzis, Athanasios G. Papavassiliou. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. IJMS 2022;23:6664
    https://doi.org/10.3390/ijms23126664
  10. Federica Giugliano, Carmine Valenza, Paolo Tarantino, Giuseppe Curigliano. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?. Expert Opinion on Investigational Drugs 2022;31:855
    https://doi.org/10.1080/13543784.2022.2095260
  11. Joanna Kałafut, Arkadiusz Czerwonka, Alinda Anameriç, Alicja Przybyszewska-Podstawka, Julia O. Misiorek, Adolfo Rivero-Müller, Matthias Nees. Shooting at Moving and Hidden Targets—Tumour Cell Plasticity and the Notch Signalling Pathway in Head and Neck Squamous Cell Carcinomas. Cancers 2021;13:6219
    https://doi.org/10.3390/cancers13246219
  12. Belén Blanco, Carmen Domínguez-Alonso, Luis Alvarez-Vallina. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy. 2021;27:5457
    https://doi.org/10.1158/1078-0432.CCR-20-3770
  13. Dan Qiu, Xiaxin Liu, Wandi Wang, Xuan Jiang, Xiaofang Wu, Jiamian Zheng, Kai Zhou, Xueting Kong, Xiuli Wu, Zhenyi Jin. TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med 2022
    https://doi.org/10.1007/s10238-022-00817-0